Dr. Jain is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
525 E 68th St
Fl 3
New York, NY 10065Phone+1 646-962-2072
Education & Training
Topiwala National Medical CollegeClass of 2007
Certifications & Licensure
FL State Medical License 2018 - 2026
NY State Medical License 2018 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated t...Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, Rohit K Jain, Christopher Dechet
Journal for Immunotherapy of Cancer. 2025-03-18 - A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.Randy F Sweis, Gurkamal S Chatta, Rohit K Jain, Helen Moon, Scott Edward Delacroix
Clinical Cancer Research. 2025-01-17 - 3 citationsOncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.Roger Li, Nancy Y Villa, Xiaoqing Yu, Joseph O Johnson, Gustavo Borjas
Nature Medicine. 2025-01-01
Press Mentions
Brooklyn ImmunoTherapeutics Announces Presentation of Ongoing Investigator Sponsored Trial of IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid TumorsJune 3rd, 2019
ProgramJanuary 13th, 2024- First-Line Combo for Cisplatin-Ineligible Bladder Cancer Just Misses Positive ResultJanuary 30th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
